Antares Pharma (NASDAQ: ATRS) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its rivals? We will compare Antares Pharma to similar businesses based on the strength of its dividends, risk, institutional ownership, earnings, profitability, analyst recommendations and valuation.
Insider and Institutional Ownership
36.8% of Antares Pharma shares are held by institutional investors. Comparatively, 63.1% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 11.6% of Antares Pharma shares are held by company insiders. Comparatively, 13.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Antares Pharma and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Antares Pharma||$53.10 million||-$15.90 million||-32.83|
|Antares Pharma Competitors||$827.23 million||$159.49 million||36.26|
Antares Pharma’s rivals have higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Antares Pharma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Antares Pharma Competitors||-127.07%||-36.30%||-10.21%|
This is a breakdown of recent ratings and recommmendations for Antares Pharma and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Antares Pharma Competitors||170||1121||2458||89||2.64|
Antares Pharma presently has a consensus price target of $4.58, suggesting a potential upside of 16.12%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 9.48%. Given Antares Pharma’s stronger consensus rating and higher probable upside, equities analysts clearly believe Antares Pharma is more favorable than its rivals.
Risk & Volatility
Antares Pharma has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Antares Pharma’s rivals have a beta of 1.06, indicating that their average stock price is 6% more volatile than the S&P 500.
Antares Pharma rivals beat Antares Pharma on 7 of the 12 factors compared.
About Antares Pharma
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.